Cargando…
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
Autores principales: | Ascierto, Paolo Antonio, Fox, Bernard A, Urba, Walter J, Anderson, Ana Carrizosa, Atkins, Michael B, Borden, Ernest C, Brahmer, Julie R, Butterfield, Lisa H, Cesano, Alessandra, Chen, Daniel S, de Gruijl, Tanja D, Dillman, Robert O, Drake, Charles G, Emens, Leisha A, Gajewski, Thomas F, Gulley, James L, Stephen Hodi Jr, F, Hwu, Patrick, Kaufman, David, Kaufman, Howard L, Lotze, Michael T, McNeel, Douglas G, Margolin, Kim A, Marincola, Francesco M, Mastrangelo, Michael J, Maus, Marcela V, Parkinson, David R, Romero, Pedro J, Sondel, Paul M, Spranger, Stefani, Sznol, Mario, Weiner, George J, Wigginton, Jon M, Weber, Jeffrey S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204613/ https://www.ncbi.nlm.nih.gov/pubmed/32300051 http://dx.doi.org/10.1136/jitc-2020-000878 |
Ejemplares similares
-
Cancer immunotherapy trials: leading a paradigm shift in drug development
por: Emens, Leisha A., et al.
Publicado: (2016) -
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)
por: Atkins, Michael B, et al.
Publicado: (2022) -
Toward integrative cancer immunotherapy: targeting the tumor microenvironment
por: Emens, Leisha A, et al.
Publicado: (2012) -
Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy
por: Wang, Ena, et al.
Publicado: (2020) -
It’s TIME for a biomarker-driven approach to cancer immunotherapy
por: Emens, Leisha A.
Publicado: (2016)